We use cookies in order to analyze traffic of this website. Your further use of this website will be considered consent. For more information visit our Cookie Policy.

News

15 Dec 20
AC Immune Receives Competitive Target ALS Foundation Grant to Accelerate the Development of Proprietary Phosphorylated TDP-43 Immuno-assay
Attachments:
PDF Version
20 Nov 20
Immunotherapy Pioneer Prof. Carl H. June Joins AC Immune’s Board of Directors
Attachments:
PDF Version
18 Nov 20
Neurologist and Psychiatrist Prof. Johannes Rolf Streffer, MD Joins AC Immune SA as Chief Medical Officer
Attachments:
PDF Version
13 Nov 20
AC Immune Reports Q3 2020 Financial Results and Provides Business Update
Attachments:
PDF Version
12 Nov 20
AC Immune to Provide Strategy and Pipeline Update During Jefferies Virtual London Healthcare Conference
Attachments:
PDF Version
09 Nov 20
AC Immune and WuXi Biologics Strengthen Strategic Partnership to Accelerate AC Immune’s Anti-TDP-43 Antibodies into Clinical Development
Attachments:
PDF Version
09 Oct 20
Competitive EU Grant Supports Collaboration to Accelerate Development of AC Immune's First-in-Class TDP-43 Diagnostic Agent
Attachments:
PDF Version
23 Sep 20
AC Immune Reports Top Line Results from TAURIEL Phase 2 Trial Evaluating Semorinemab in Early Alzheimer’s Disease
Attachments:
PDF Version
11 Sep 20
AC Immune to Showcase Anti-Tau Portfolio at H.C. Wainwright 22nd Annual Global Investment Conference
Attachments:
PDF Version
05 Aug 20
AC Immune Reports Q2 2020 Financial Results and Provides Business Update
Attachments:
PDF Version
03 Aug 20
AC Immune Initiates IND-Enabling Studies for First-in-Class Antibody Targeting TDP-43 to Treat Neurodegeneration
Attachments:
PDF Version
30 Jul 20
AC Immune Wins Prestigious Award to Develop a “Game-Changing” Parkinson’s Diagnostic Tool
Attachments:
PDF Version
28 Jul 20
AC Immune Demonstrates Enhanced Performance of First-in-class Parkinson’s Diagnostic Agent
Attachments:
PDF Version
23 Jul 20
AC Immune to Present Advances in Two of the Company’s World Leading Programs at the Upcoming Alzheimer’s Association International Conference
Attachments:
PDF Version
16 Jul 20
AC Immune Advances phospho-Tau Alzheimer’s Vaccine in Phase 1b/2a Study
Attachments:
PDF Version
07 Jul 20
Tau-PET Tracer PI-2620 Could Set New Standards for an Improved Diagnosis of Progressive Supranuclear Palsy
Attachments:
PDF Version
26 Jun 20
AC Immune Announces Results of Annual General Meeting
Attachments:
PDF Version
15 May 20
AC Immune CEO to Showcase Novel Target Programs at UBS Global Healthcare Conference
Attachments:
PDF Version
04 May 20
AC Immune Reports Q1 2020 Financial Results and Provides Business Update
Attachments:
PDF Version
02 Apr 20
AC Immune Presents the Latest Preclinical Data on Novel Drug Targets for Neurodegenerative Diseases
Attachments:
PDF Version
30 Mar 20
AC Immune Reports Full-Year 2019 Financial Results and Provides 2020 R&D Outlook
Attachments:
PDF Version
23 Mar 20
AC Immune Receives Second Milestone and New Milestone to Increase the Potential Deal Value of Lilly Morphomer™ Tau Partnership
Attachments:
PDF Version
20 Mar 20
Internationally Renowned Neurologist Dr. Juan Fortea Joins AC Immune’s Clinical Advisory Board
Attachments:
PDF Version
05 Mar 20
AC Immune to Present New Data Demonstrating the Depth of its Neurodegenerative Programs at the Upcoming Advances in Alzheimer’s and Parkinson’s Therapies Focus Meeting
Attachments:
PDF Version